Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Pancreatic Neoplasms 8Neoplasms 7Leukemia, Myeloid, Acute 6Colorectal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Prostatic Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 4Neoplasm Metastasis 4Carcinoma, Transitional Cell 4Carcinoma, Merkel Cell 4Triple Negative Breast Neoplasms 3Myelodysplastic Syndromes 3Multiple Myeloma 3Melanoma 3Lymphoma, Non-Hodgkin 3Leukemia, Lymphocytic, Chronic, B-Cell 3Urinary Bladder Neoplasms 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Lymphoma, B-Cell 2Lymphoma 2Lung Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Colonic Neoplasms 2Carcinoma 2Uterine Cervical Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1

Interventions

pembrolizumab 157Gemcitabine 140Capecitabine 123Paclitaxel 121Fluorouracil 117Oxaliplatin 110Bevacizumab 106Nivolumab 99Docetaxel 98Leucovorin 97Cisplatin 90Radiosurgery 88Irinotecan 88Carboplatin 86Cyclophosphamide 72Cetuximab 72Magnetic Resonance Spectroscopy 68Specimen Handling 60Radiotherapy 60Trastuzumab 59Biopsy 59Ipilimumab 53Drug Therapy 51Everolimus 48Pemetrexed 46Albumin-Bound Paclitaxel 45130-nm albumin-bound paclitaxel 44Doxorubicin 42Fulvestrant 40aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neoplasm Metastasis × ALT-803 × Clear all
NCT04898543 2025-12-11

QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors

ImmunityBio, Inc.

Phase 1 Active not recruiting
50 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01946789 2025-01-22

A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors

Altor BioScience

Phase 1 Completed
26 enrolled 22 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms

NCT03127098 2024-08-06

QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

NantCell, Inc.

Phase 1/2 Terminated
3 enrolled 6 charts
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Thyroid Neoplasms

NCT02559674 2020-01-27

QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel

Altor BioScience

Phase 1 Completed
8 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡